FDA warns SeeNext Venture over unapproved, misbranded NumbSkin lidocaine creams sold online.
What happened
FDA reviewed numbskin.com in October 2023 and found NumbSkin 5% and 10.56% lidocaine numbing creams sold for use before sensitive cosmetic procedures. FDA said the products are unapproved new drugs and misbranded because they do not meet OTC monograph conditions: lidocaine exceeds the permitted 0.5% to 4% range and labeling includes tattooing, piercing, and other uses not covered.
What FDA found
The creams are unapproved new drugs because they are marketed without an FDA-approved application and do not meet the OTC external analgesic monograph.
section 505(a) of the FD&C Act, 21 U.S.C. 355(a)The products are misbranded because they are nonprescription drugs that do not comply with section 505G and are not approved under section 505.
section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)The labeled lidocaine concentrations of 5% and 10.56% exceed the 0.5% to 4% range permitted for OTC external analgesic products under M017.
Over-the-Counter Monograph M017; section 505G(a)(1)Labeling claims for tattooing, piercing, laser hair removal, microblading, and similar procedures are not included in M017.
section 505G of the FD&C Act; M017The products are also labeled for anorectal use but do not meet the OTC anorectal monograph M015 at these lidocaine concentrations.
Over-the-Counter Monograph M015; section 505G
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to address the violations, explain how recurrence will be prevented, and send supporting documentation. If the company believes the products are not in violation, it must include reasoning and supporting information.
Who should pay attention
- online sellers and distributors of topical numbing creams
- cosmetic and tattoo clinics that use or recommend numbing products
- brands relying on OTC monograph claims for lidocaine products
This is a summary. Read the original letter on fda.gov.